Myeloma Paper of the Day, November 18th, suggested by Robert Orlowski
Robert Orlowski shared a post on X:
“Myeloma Paper of the Day: Retrospective study of 8 AL amyloidosis patients treated with teclistamab finds 100% VGPR rate with 6 hematologic CR in median 88 days, cardiac improvement in 4/5 and 3/5 renal responses.”
Safety and Efficacy of Teclistamab in Patients With Relapsed or Refractory AL Amyloidosis
Authors: Margaret Stalker, Alfred Garfall, Adam Cohen, Dan T. Vogl, Mia Djulbegovic, Sandra Susanibar-Adaniya, Edward Stadtmauer, Oxana Megherea, Adam J. Waxman.
More posts featuring Robert Orlowski.
Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023